Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Inhaled Nitrite in Subjects With Pulmonary Hypertension

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by University of Pittsburgh
Information provided by (Responsible Party):
University of Pittsburgh Identifier:
First received: September 6, 2011
Last updated: January 23, 2014
Last verified: January 2014

This is a single-center, open label phase II study to evaluate the effect of inhaled nitrite delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with pulmonary arterial hypertension undergoing right heart catheterization.

A total of 30 subjects with a confirmed diagnosis of pulmonary arterial hypertension and meet all inclusion/exclusion criteria will be enrolled in the study which will entail a single right heart catheterization and nebulized nitrite dose of 45mg with one subsequent dosage of 90 mg.

Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: Inhaled Nitrite
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Change in pulmonary vascular resistance [ Time Frame: from time zero, at times 15, 30 and 45 minutes of nebulization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in mean pulmonary artery pressure, transpulmonary gradient and cardiac output [ Time Frame: from time zero, at times 15, 30 and 45 minutes of nebulization ] [ Designated as safety issue: No ]
  • Change in systemic blood pressure [ Time Frame: from time zero, at times 15, 30 and 45 minutes of nebulization ] [ Designated as safety issue: Yes ]
  • Change in SVR, RV systolic (dP/dtmax/IP, PWRmax/EDV, RV EF, TAPSE), RV diastolic (dP/dtmin, Tau) [ Time Frame: from time zero, at times 15, 30 and 45 minutes of nebulization ] [ Designated as safety issue: No ]
    RV measurements are completed at baseline, 2nd baseline and final measurements

  • Change in pulmonary vascular impedance / Wave Intensity [ Time Frame: from time zero, at times 15, 30 and 45 minutes of nebulization ] [ Designated as safety issue: No ]
  • Plasma nitrite concentration in mixed venous blood [ Time Frame: pre-dose, 15, 30, 45 minutes and 1 hour after dose ] [ Designated as safety issue: No ]
  • PCW pullback nitrite levels and cGMP levels [ Time Frame: post-dose ] [ Designated as safety issue: No ]
  • Change in pulmonary arterial input impedance [ Time Frame: from time zero, at times 15, 30 and 45 minutes of nebulization ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: April 2012
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Inhaled Nitrite Drug: Inhaled Nitrite
Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite


Ages Eligible for Study:   18 Years to 78 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Diagnosis of RHC confirmed WHO Group I PAH (n=20)

Idiopathic, primary or familial pulmonary arterial hypertension • PAH associated with one of the following connective tissue diseases:

PAH associated with exposure to drugs and toxins (eg, anorexigens, L-tryptophan, toxic rapeseed oil)

  • If on current treatment with approved PDE5-I and/or ETRA, the dose is at package-insert recommended dosages as monotherapy or in combination with any continuously administered subcutaneous or intravenous prostacyclin analog
  • Stable PAH for at least 3 months if on therapy WHO Group III PH (n = 10)
  • Has WHO functional class III-IV symptoms
  • Had the diagnosis of PH confirmed by a cardiac catheterization Both WHO Group I PAH and WHO Group III PH


  • Age 18-78
  • Able to participate in right heart catheterization.
  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study;
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;

Exclusion Criteria:

  • Age less than 18 years or greater than 78 years.
  • Baseline systemic hypotension, defined as MAP less than 50 mmHg;
  • Required intravenous inotropes within 30 days prior to study participation;
  • Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening;
  • Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class B-C);
  • Has chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL at Screening or requires dialytic support;
  • Has a hemoglobin concentration <9 g/dL at Screening;
  • History of atrial septostomy;
  • Repaired or unrepaired congenital heart disease (CHD);
  • Pericardial constriction;
  • Restrictive or congestive cardiomyopathy;
  • Left ventricular ejection fraction <40% by multiple gated acquisition scan (MUGA), angiography or echocardiography;
  • Symptomatic coronary disease with demonstrable ischemia;
  • Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study;
  • Has a psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study. This includes subjects with a recent history of abusing alcohol or illicit drugs 30 days prior to study screening Day 0 and for the duration of the study;
  • Poorly controlled asthma defined by active wheezing and/or cough with FEV1 < 70% predicted, responsive to inhaled BD (>15% increase in FEV1 with BD);
  • Investigators, study staff or their immediate families;
  • Clinically significant intercurrent illness (including lower respiratory tract infection) or clinically significant surgery within 4 weeks before the administration of study drug;
  • Personal or family history of RBC CYP B5 reductase deficiency;
  • Known or suspected hypersensitivity or allergic reaction to sodium nitrite or saccharin;
  • Personal history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or any contraindication to receiving methylene blue;
  • History of hypersensitivity or idiosyncratic reaction to drugs from multiple drug classes;
  • If female, is pregnant or breast feeding, or has a positive pregnancy test result predose;
  • Receipt of an investigational product or device, or participation in a drug research study within a period of 15 days (or 5 half-lives of the drug, whichever is longer) before the first dose of study drug;
  • Blood loss or blood donation >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of study drug;
  • Clinical right heart catheterization < 2 weeks from treatment visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01431313

Contact: Marc A. Simon, MD 412-802-3131

United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Marc A. Simon, MD    412-802-3131   
Contact: Pamela M. White, RN    412-624-3147   
Principal Investigator: Marc A. Simon, MD         
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: Marc A. Simon, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: University of Pittsburgh Identifier: NCT01431313     History of Changes
Other Study ID Numbers: PRO11080686
Study First Received: September 6, 2011
Last Updated: January 23, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
pulmonary arterial hypertension

Additional relevant MeSH terms:
Hypertension, Pulmonary
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases processed this record on November 25, 2014